merck millipore,默克密理博,528205,Plasminogen Activator Inhibitor-1, Human, Recombinant

搜索"Merck Millipore 密理愽"产品

Merck Millipore 默克密理愽

当前位置：首页 > >Merck Millipore > 生命科学研究
生命科学研究

merck millipore,默克密理博,528205,Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem
产品名称：Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem
产品型号：528205
The Plasminogen Activator Inhibitor-1, Human, Recombinant controls the biological activity of Plasminogen Activator. This small molecule/inhibitor is primarily used for Protease Inhibitors application More>>

merck millipore,默克密理博,528205,Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem

产品介绍

merck millipore,默克密理博,528205,Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem

描述
概述	PAI-1 is the primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified of latent material. PAI-1 is a marker for acute myocardial infarction and several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Reported to be an important prognostic factor in breast cancer patients. PAI-1 is highly stable when stored at or below pH 6.6.
产品目录编号	528205
品牌系列	Calbiochem®
同义词	PAI-1

参考
参考	Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995. Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272. Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195. Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713. Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307. Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523. Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673. Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.

参考

Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.

产品信息
具有ATP竞争性	N
形式	Liquid
配方	In 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
Molar Mass	43000
可逆	N

生物信息
生物活性	≥90% by uPA assay
主靶	Tissue plasminogen activator (tPA) and urokinase (uPA)
纯度	≥98% by SDS-PAGE

理化信息
细胞可渗透	N

储存和货运信息
货运代码	Dry Ice Only
毒性	Standard Handling
储存	≤ -70°C
避免冻结 / 解冻	Avoid freeze/thaw
无需冷冻	No
特殊指南	Following initial thaw, aliquot and freeze (-70°C).